Core Insights - The news highlights that Zhong Huijuan, the founder and CEO of Hansoh Pharmaceutical, has become China's richest woman with a wealth of 141 billion yuan, marking a significant milestone in the 20-year history of the Hurun Women's Entrepreneur List [2][3] Company Overview - Hansoh Pharmaceutical was founded on July 26, 1995, originally as Jiangsu Haosen, a Sino-foreign joint venture [3][4] - The company underwent several restructurings and was listed on the Hong Kong Stock Exchange on June 14, 2019 [4] Business Strategy and Development - The company has focused on a development strategy of "combining imitation and innovation," establishing a foundation with generic drugs while seeking breakthroughs with innovative drugs [5] - Since 2002, Hansoh has been developing Class 1.1 innovative drugs, with its first approved innovative drug, Mylinda, launched in 2014 [5] Financial Performance - In the first half of this year, Hansoh Pharmaceutical achieved revenue of 7.434 billion yuan, a year-on-year increase of 14.3%, and a net profit of 3.135 billion yuan, up 15% [5] - Innovative drugs and cooperative product sales contributed significantly to the revenue, with innovative drugs accounting for approximately 82.7% of total revenue [6] Market Position and Stock Performance - As of October 31, the market capitalization of Hansoh Pharmaceutical reached 212.9 billion yuan, with the stock price doubling this year [6] - Zhong Huijuan and her daughter hold over 60% of the company's shares, indicating strong family control [6] Recent Developments - Hansoh's innovative drug for non-small cell lung cancer, Amelot, was approved for sale in the UK, marking the company's first entry into the overseas market [7] - The company has also licensed overseas rights for its investigational CDH17-targeted antibody-drug conjugate to Roche, receiving an upfront payment of 80 million USD and potential milestone payments of up to 1.45 billion USD [7]

Core Viewpoint - The article highlights the rise of Zhong Huijuan, founder and CEO of Hansoh Pharmaceutical, as the new richest woman in China, with a wealth of 141 billion yuan, marking a significant milestone in the pharmaceutical industry and women's leadership in business [3][4]. Company Overview - Hansoh Pharmaceutical was founded on July 26, 1995, originally as Jiangsu Haosen, a Sino-foreign joint venture [5]. - The company underwent several restructurings and was listed on the Hong Kong Stock Exchange on June 14, 2019 [7]. - The company focuses on the development of innovative drugs, particularly in oncology, anti-infection, central nervous system, metabolism, and autoimmune diseases [8]. Financial Performance - In the first half of the year, Hansoh Pharmaceutical achieved revenue of 7.434 billion yuan, a year-on-year increase of 14.3%, and a net profit of 3.135 billion yuan, up 15% [8]. - Innovative drugs and cooperative product sales accounted for approximately 82.7% of the company's total revenue, with sales from innovative drugs reaching 6.145 billion yuan [8]. Market Position and Growth - The company's stock price has doubled this year, with a market capitalization reaching 212.9 billion yuan as of October 31 [8]. - Zhong Huijuan and her daughter hold over 60% of the company's shares, indicating strong family control and confidence in the company's future [8]. Recent Developments - Hansoh Pharmaceutical's innovative drug for non-small cell lung cancer, Amelot, was approved for sale in the UK, marking the company's first entry into the overseas market [9]. - The company has also licensed overseas rights for its investigational CDH17-targeted antibody-drug conjugate to Roche, which includes an upfront payment of $80 million and potential milestone payments of up to $1.45 billion [9].

Core Insights - The news highlights that Zhong Huijuan has become the richest woman in China, with a wealth of 141 billion yuan, according to the 2025 Hurun Women Entrepreneurs List, marking her as the first female billionaire in the life and health sector in the list's history [1] Company Overview - Zhong Huijuan is the founder, chairperson, CEO, and executive director of Hansoh Pharmaceutical, which was established on July 26, 1995, originally as Jiangsu Haosen, a Sino-foreign joint venture [3][4] - The company underwent several transformations and was listed on the Hong Kong Stock Exchange on June 14, 2019 [4] Business Strategy - Hansoh Pharmaceutical has adopted a development strategy of "combining imitation and innovation," focusing on the research and development of innovative drugs since 2002 [4] - The company has successfully developed and launched two innovative drugs, with its first innovative drug, Mai Ling Da, approved in 2014 [4] Financial Performance - In the first half of this year, Hansoh Pharmaceutical achieved a revenue of 7.434 billion yuan, a year-on-year increase of 14.3%, and a net profit of 3.135 billion yuan, up 15% [5] - The sales revenue from innovative drugs and cooperative products accounted for approximately 82.7% of the company's total revenue [5] Market Position - As of October 31, the market capitalization of Hansoh Pharmaceutical reached 212.9 billion yuan, with the stock price doubling this year [5] - The company has made significant strides in its innovative drug business, including the approval of its non-small cell lung cancer drug in the UK and a licensing agreement with Roche for an ADC product, which includes an upfront payment of 80 million USD [5]